Compare ARK Fintech Innovation ETF (ARKF) vs Revvity Inc (RVTY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Fintech Innovation ETF vs Revvity Inc — how do they compare? ARK Fintech Innovation ETF trades at $41.45, while Revvity Inc trades at $111.77 (market cap $12.53B). The key difference: Revvity Inc pays a 0.25% dividend while ARK Fintech Innovation ETF pays none, and Revvity Inc is trading nearer its 52-week high, ARK Fintech Innovation ETF nearer its low. Which is the better fit depends on your goals.
| ARKF | RVTY | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $58.82 | $117.75 |
52-Week Low | $36.14 | $82.26 |
Market Cap | — | $12.53B |
Enterprise Value | — | $15.02B |
Dividend Yield | — | 0.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKF trades at $41.63, up 0.43% with bullish technical signals from moving averages and strong trend strength (ADX 39.69). The stock faces resistance at $42 with support at $41. Recent coverage highlights institutional interest in Cathie Wood's and Bill Ackman's overlapping investments in Magnificent Seven stocks.
The ETF's outlook is supported by technical momentum but lacks fundamental financial data disclosure. Key risks include market volatility and dependency on top holdings performance. Institutional overlap suggests confidence in selected growth stocks, though valuation metrics remain undisclosed.
Revvity (RVTY) trades at $112.29, down 0.58% on the day, with strong technical momentum showing bullish moving averages and key support at $110. The company demonstrates consistent earnings beats with Q1 2026 EPS of $1.06 exceeding expectations, maintaining solid profitability with 54.32% gross margins. Recent developments include AI integration partnerships with Anthropic and FDA clearance for new diagnostic tests, signaling innovation in life sciences.
RVTY presents a mixed outlook with analyst consensus leaning bullish (52% buy ratings) but trading above the $109.38 price target. While strong operational cash flow ($583M in 2025) and AI expansion provide upside potential, elevated P/E ratio (53.99) and declining net cash flow (-$243M in 2025) warrant caution amid competitive pressures in healthcare technology.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Fintech Innovation ETF
ARKF is an actively managed ETF that invests in companies leading the way in fintech innovation. Key themes include mobile payments, digital wallets, blockchain technology, and frictionless funding platforms.
Read more on ARKF →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
